$PRME
Prime Medicine, Inc. Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024022473 Filed on May 10, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$591.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.60M	$11.16M
YoY Change	18.21%	21.91%
% of Gross Profit
Research & Development	$43.07M	$37.77M
YoY Change	24.48%	22.33%
% of Gross Profit
Depreciation & Amortization	$1.538M	$1.315M
YoY Change	37.57%	25.0%
% of Gross Profit
Operating Expenses	$55.67M	$48.93M
YoY Change	23.01%	22.23%
Operating Profit	-$55.67M	-$48.34M
YoY Change	23.01%	20.75%
Interest Expense	$172.0K	$1.166M
YoY Change	-33.85%	-168.55%
% of Operating Profit
Other Income/Expense, Net	$211.0K	$2.714M
YoY Change	-92.73%	525.35%
Pretax Income	-$55.46M	-$45.63M
YoY Change	30.96%	15.22%
Income Tax	-$134.0K	$134.0K
% Of Pretax Income
Net Earnings	-$55.33M	-$45.76M
YoY Change	30.53%	16.15%
Net Earnings / Revenue		-7742.98%
Basic Earnings Per Share	-$0.46	-$0.44
Diluted Earnings Per Share	-$0.46	-$0.44
COMMON SHARES
Basic Shares Outstanding	120.0M shares	119.9M shares
Diluted Shares Outstanding	119.2M shares	104.5M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$162.9M	$210.7M
YoY Change	-21.55%	-13.42%
Cash & Equivalents	$55.60M	$94.16M
Short-Term Investments	$107.3M	$116.6M
Other Short-Term Assets	$3.736M	$2.728M
YoY Change	-65.64%	-31.49%
Inventory
Prepaid Expenses	$4.199M	$4.203M
Receivables
Other Receivables
Total Short-Term Assets	$170.8M	$217.7M
YoY Change	-21.83%	-14.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.81M	$23.93M
YoY Change	15.83%	10.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$779.0K
YoY Change	-100.0%	-52.67%
Total Long-Term Assets	$88.90M	$93.73M
YoY Change	42.53%	47.73%
TOTAL ASSETS
Total Short-Term Assets	$170.8M	$217.7M
Total Long-Term Assets	$88.90M	$93.73M
Total Assets	$259.7M	$311.4M
YoY Change	-7.53%	-1.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.638M	$10.08M
YoY Change	-15.52%	120.96%
Accrued Expenses	$10.90M	$7.612M
YoY Change	-49.87%	0.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.75M	$24.44M
YoY Change	-27.76%	2.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$42.37M	$43.04M
YoY Change	255.04%	203.18%
Total Long-Term Liabilities	$42.37M	$43.04M
YoY Change	255.04%	203.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.75M	$24.44M
Total Long-Term Liabilities	$42.37M	$43.04M
Total Liabilities	$63.12M	$67.62M
YoY Change	54.84%	77.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$592.4M	-$537.1M
YoY Change	57.97%	61.49%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$196.6M	$243.8M
YoY Change
Total Liabilities & Shareholders Equity	$259.7M	$311.4M
YoY Change	-7.53%	-1.76%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$55.33M	-$45.76M
YoY Change	30.53%	16.15%
Depreciation, Depletion And Amortization	$1.538M	$1.315M
YoY Change	37.57%	25.0%
Cash From Operating Activities	-$45.49M	-$67.71M
YoY Change	11.44%	62.91%
INVESTING ACTIVITIES
Capital Expenditures	$1.902M	$2.324M
YoY Change	-3.74%	16.26%
Acquisitions
YoY Change
Other Investing Activities	$8.796M	-$34.71M
YoY Change	-70.52%	225.41%
Cash From Investing Activities	$6.894M	-$37.03M
YoY Change	-75.26%	192.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	35.00K	$157.3M
YoY Change	-53.33%	231263.24%
NET CHANGE
Cash From Operating Activities	-45.49M	-$67.71M
Cash From Investing Activities	6.894M	-$37.03M
Cash From Financing Activities	35.00K	$157.3M
Net Change In Cash	-38.56M	$52.59M
YoY Change	199.28%	-197.1%
FREE CASH FLOW
Cash From Operating Activities	-$45.49M	-$67.71M
Capital Expenditures	$1.902M	$2.324M
Free Cash Flow	-$47.39M	-$70.03M
YoY Change	10.74%	60.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	48932000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-45761000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39397000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48341000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40033000	usd
CY2023Q1	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-1701000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-45761000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4203000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19057000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2728000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2254000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	217654000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	142976000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23926000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55528000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13941000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	779000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	779000	usd
CY2024Q1	us-gaap	Assets Assets	311383000	usd
CY2023Q4	us-gaap	Assets Assets	193851000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10078000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19537000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7612000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2024Q1	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	0	usd
CY2023Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	13500000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6751000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9276000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24441000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56423000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37042000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4357000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	134000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2024Q1	prme	Research And Development Funding Liability Noncurrent ResearchAndDevelopmentFundingLiabilityNoncurrent	6000000	usd
CY2023Q4	prme	Research And Development Funding Liability Noncurrent ResearchAndDevelopmentFundingLiabilityNoncurrent	0	usd
CY2024Q1	us-gaap	Liabilities Liabilities	67617000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	60780000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120021274	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120021274	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	780950000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	624414000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-95000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-537091000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491330000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	243766000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	311383000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193851000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	591000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37774000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30880000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11158000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9153000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	40033000	usd
CY2024Q1	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	1166000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1548000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2135000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2714000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	434000	usd
CY2024Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-45627000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-39599000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	134000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-202000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45761000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-45761000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39397000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39397000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104466178	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104466178	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89064895	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89064895	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-80000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	179000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45841000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39218000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	132055000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18800000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	436000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5209000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-80000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	243766000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1681000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39397000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	278801000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-45761000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39397000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5209000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1681000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3348000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2831000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1315000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1052000	usd
CY2024Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	1166000	usd
CY2023Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1701000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	675000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	611000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	134000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-202000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2794000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1285000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5880000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-504000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4475000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4046000	usd
CY2024Q1	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	-13500000	usd
CY2023Q1	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	0	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3462000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2781000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67707000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41561000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	72500000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	35000000	usd
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	107208000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	45666000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2324000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1999000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37032000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12665000	usd
CY2024Q1	prme	Proceeds From Issuance Follow On Offering ProceedsFromIssuanceFollowOnOffering	132055000	usd
CY2023Q1	prme	Proceeds From Issuance Follow On Offering ProceedsFromIssuanceFollowOnOffering	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18800000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2024Q1	prme	Proceeds From Research And Development Funding Liability ProceedsFromResearchAndDevelopmentFundingLiability	6000000	usd
CY2023Q1	prme	Proceeds From Research And Development Funding Liability ProceedsFromResearchAndDevelopmentFundingLiability	0	usd
CY2024Q1	prme	Proceeds From Espp Offerings ProceedsFromESPPOfferings	436000	usd
CY2023Q1	prme	Proceeds From Espp Offerings ProceedsFromESPPOfferings	0	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	68000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	157327000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52588000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54158000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107658000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146958000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107658000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146958000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94162000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133462000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44935000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	833000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2603000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-537100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	210700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to the valuation of the Company’s common stock and stock-based awards, and the valuation of the related party forward contract liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></div>
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	210262000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	104300000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	110026000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	83000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	109943000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	74654000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	74639000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	109943000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	74639000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	31876000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	43793000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32725000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30143000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8799000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7484000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23926000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1315000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1052000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5868000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18584000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21339000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20812000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	20853000	usd
CY2024Q1	prme	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	118079000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	205535000	usd
CY2024Q1	prme	Lessee Operating Lease Liability Payments Related To Leases But Not Yet Commenced LesseeOperatingLeaseLiabilityPaymentsRelatedToLeasesButNotYetCommenced	129866000	usd
CY2024Q1	prme	Common Stock Par Or Stated Value Per Share Under Amendment CommonStockParOrStatedValuePerShareUnderAmendment	0.0001
CY2024Q1	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7641863	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.79
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3898410	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.23
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9664	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.73
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	139885	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.59
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11390724	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.24
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2838246	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.64
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11390724	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.24
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5209000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1681000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45761000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-45761000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39397000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39397000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104466178	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104466178	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89064895	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89064895	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15928769	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14475709	shares

Files In Submission

Name	View Source	Status
0001628280-24-022473-index-headers.html	Edgar Link	pending
0001628280-24-022473-index.html	Edgar Link	pending
0001628280-24-022473.txt	Edgar Link	pending
0001628280-24-022473-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20240331.htm	Edgar Link	pending
prme-20240331.xsd	Edgar Link	pending
q12024ex311.htm	Edgar Link	pending
q12024ex312.htm	Edgar Link	pending
q12024ex321.htm	Edgar Link	pending
q12024ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prme-20240331_cal.xml	Edgar Link	unprocessable
prme-20240331_def.xml	Edgar Link	unprocessable
prme-20240331_lab.xml	Edgar Link	unprocessable
prme-20240331_pre.xml	Edgar Link	unprocessable
prme-20240331_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine, Inc. Stock $prme

2024 Q2 Form 10-Q Financial Statement

#000162828024022473 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine, Inc. Stock $prme

2024 Q2 Form 10-Q Financial Statement

#000162828024022473 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine, Inc. Stock $prme